key: cord-0907773-ujkc82ht authors: Sertoglu, Erdim; Yucel, Cigdem; Balık, Ahmet Rıfat; Taşçı, Cantürk; Bilge, Sedat; Ertuğrul, Meryem Sebla; Nazaroğlu, Namık Kemal; Ozgurtas, Taner title: Evaluation Of Erythrocyte Membrane Fatty Acid Compositions in Compliance with IL-6 Levels in COVID-19 Patients date: 2021-12-26 journal: Nutrition DOI: 10.1016/j.nut.2021.111581 sha: d773ec53d4bc14db447dfb33fd576b4b8eff205b doc_id: 907773 cord_uid: ujkc82ht Background : The cytokine storm presented by hyper-immune response is related to bad prognosis in COVID-19 patients. IL-6 is one of the most prominent cytokines especially on mucosal surfaces during infection, causing cytokine storm. Polyunsaturated fatty acids (PUFAs) are the precursors of eicosanoids which play critical roles in immune regulation and inflammation. The balance between ω3 and ω6 levels in the cell membrane has a critical role in regulating the equilibrium between pro-inflammatory and inflammatory processes and also induce IL-6 production. The present study focuses on the inflammatory/anti-inflammatory mechanisms in COVID-19 patients over PUFAs and to relate their levels with disease prognosis and severity. Methods : A total of 106 patients were included in the study. The patients were divided into 3 groups according to their IL-6 levels (Group 1=IL-6< 35 pg/mL, Group 2= IL-6 >35<300 pg/mL and Group 3= IL-6>300 pg/mL). Erythrocyte membrane PUFA compositions were analyzed between groups. Results : GLA levels and ω-6/ω-3 ratio were significantly increased in all comparison groups (p<0.05). Total ω-6 and AA/EPA ratio has only showed statistically significant difference between Group 1 and Group 3 (p<0.05). There was a moderately negative correlation between total ω-3 and IL-6 and procalcitonin. There were positive correlations with ω-6/ω-3 ratio inflammatory markers and total ω-6 index also showed moderately positive correlation with IL-6, procalcitonin and D-dimer levels. Conclusion : ω-3 PUFAs, and AA/EPA ratio can be a systemic sign of bad prognosis, increased lung damage and high mortality in COVID-19 patients together with IL-6. Coronaviruses are a family of zoonotic viruses which may cause lower respiratory tract infections and fatal respiratory failure characterized by hyperinflammation [1] . COVID-19 virus, which caused a global pandemic in year 2019, triggers a variety of symptoms including dry cough, dyspnea, tremors, myalgia, headache, loss of taste and smell and gastrointestinal discomfort. The virus causes more severe disease in especially obese, diabetic, immune compromised individuals and in the elderly with co-morbidities [2] . Although the virus affects multiple organ systems, the cardinal feature of the disease is defined as respiratory failure. Inflammatory response plays an important role in COVID-19 prognosis. The aggressive inflammatory response triggered by the disease and high amounts of pro-inflammatory cytokines released into the circulation cause a situation called "cytokine storm". The cytokine storm presented by hyper-immune response is related to severe lung damage, multiple organ failure and bad prognosis in COVID-19 patients [3, 4] . As a proinflammatory and multi-factorial cytokine, besides triggering antibody production causing secondary immune response and increasing the synthesis of acute phase proteins such as C-reactive protein (CRP) and fibrinogen it is one of the most prominent cytokines especially on mucosal surfaces during infection [5, 6] . In addition, a relationship between IL-6 and respiratory failure has been detected especially in patients with severe lung damage. And as indicated recently by Hojyo et al., the heavy viral burden triggers IL-6 production in severe patients which in turn causes the cytokine storm with high mortality [7] . While linoleic acid (LA), γ-linolenic acid (GLA), dihomo-γ-linolenic acid (DGLA), arachidonic acid (AA), α-linolenik Acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are all polyunsaturated fatty acids (PUFAs); only LA and ALA are essential fatty acids, and the remaining are all synthesized from these two molecules through desaturation and elongation reactions [8] . The most important role of these PUFAs is being the precursor of eicosanoids which are known to play critical roles in immune regulation and inflammation. They also induce the formation of pro-inflammatory molecules causing the release of inflammatory mediator cytokines like IL-1β, 6 and 8 and tumor necrosis factor-α (TNF-α) [9, 10] . ω3 PUFAs (EPA and DHA) are proclaimed to be the basis of the anti-inflammatory effects, while ω-6 PUFAs (particularly AA) are potent mediators of inflammation and cell proliferation [11] [12] [13] . These anti-inflammatory effects of ω3 PUFAs can be competitive with ω6 PUFAs, because ω3 PUFAs are competitive substrates in the metabolism of ω6 PUFAs [14] . Hence, the balance between ω3 and ω6 levels in the bloodstream and especially in the cell membrane has a critical role in regulating the equilibrium between pro-inflammatory and inflammatory processes. In the light of this information, we aimed to evaluate the ω3 and ω6 PUFAs levels and role of these fatty acids together with IL-6, in the development of cytokine storm in SARS-CoV-2 patients. Thus, by understanding the pro-inflammatory/anti-inflammatory mechanisms in COVID-19 patients over PUFAs, it will be possible to obtain data at the cellular level to identify the possible pathways important in disease prognosis. The study was approved by the local ethics committee of Gulhane School of Medicine (2021-13), which was conducted according to the Helsinki Declaration. 106 patients were included in the study and the patients will be divided into 3 groups according to the following criteria: 1-According to information provided by the Beckman Coulter Access IL-6 Assay kit which is used to measure serum IL-6 levels in our study, IL-6 ˃35 pg/mL was determined to identify 85.4%6 of patients who had PaO2/FiO2 ratio <150 mmHg, which is also the indicative of the risk of mechanical ventilation (https://www.beckmancoulter.com/products/immunoassay/accessil-6-assay). On the other hand, there are also publications in the literature that use 35 as cut-off for risk of mortality and intensive care unit (ICU) admission [15, 16] . Therefore, the first patient group consists of PCR-confirmed COVID-19 patients with ≤ 35 pg/mL (32 patients). 2-In a retrospective study was aiming to assess IL-6 levels in critically ill COVID-19 patients admitted to ICU and to evaluate their relationship with patient's severity and outcome, Gorham et al. suggested value of 300 pg/mL. This threshold value is also indicated by Li et al. and Wang et al. that can be used in admission to ICU and/or can be used to discriminate the critical group of patients than severe [17] [18] [19] . In the light of the recent literature, 300 pg/mL value has been taken to discriminate critical patients from others (45 patients). 3-Our last group of patients consist of PCR-approved COVID-19 patients with IL-6 values ˃300 pg/mL (29 patients). Venous blood samples were collected to K2-EDTA-containing tubes. Hematocrit levels were determined with Beckman Coulter Unicel DxH 800 Coulter Cellular Analysis System (Indianapolis, Indiana, United States) for all samples. Afterwards, the erythrocytes were separated from the plasma by centrifugation (3000 rpm, 1500 × g, for 10 min) and washed with an equal volume of saline. Following the removal of the saline, the cells were resuspended with saline to Hct of 45%. These erythrocyte suspensions (ES) and plasma were stored in a freshly BHT-treated Eppendorf vials at -80 o C as previously described [20] . ES were thawed prior to sample preparation. 200 μL of ES and 2 mL of 3 N methanolic HCl including internal standard (Heptadecanoic acid (C 17:0) at 0.1μM concentration) were added in to the 13 ml screw cap glass tubes. Transmethylation was performed at 90 o C for 3 h. After cooling the tubes to room temperature, 2 ml hexane was added, the tubes were closed again and vortexed for 10 s. The upper phase was transferred to clean glass tube and evaporated in the speedvac (ScanSpeed 32, 1900 rpm, 25 o C). Finally, the residue was resuspended with 100 μL of hexane and the sample was transferred to a GC injection vial with a screw cap [9, 20] . IL-6 levels were measured with Beckman Coulter Access autoanalyzer with chemiluminescent immunoassay method. Analytical CV was < 12% and analytical sensitivity was 0.5 pg/mL. Linearity of the assay was 2 to 1500 pg/mL while automatic 2-fold dilution was made by the analyzer for samples with IL-6 values greater than 1500 pg/mL. Procalcitonin (PCT) levels were also detected with Beckman Coulter Access autoanalyzer with chemiluminescent immunoassay method. LoQ was 0.02 ng/mL and CV ≤8% at concentrations of ≥0.150 ng/mL. Analytical measuring range was 0.05-100 ng/mL. CRP levels were detected with Beckman Coulter AU 5800 autoanalyzer with immune-turbidimetric method with assay range 0.2 to 160 mg/L. Ddimer was measured with Sysmex CS-2500 autoanalyzer with particle enhanced immunoturbidimetric assay. The analytical CV was 8.4% with diagnostic sensitivity of 99.4% at 0.50 mg/L FEU cut-off. Whole blood analysis was carried out with Beckman Coulter DxH 900 analyzer with volume-conductivity-scatter principle. An Agilent GC/MS has been used for analysis. It is composed of 7890B GC System coupled with a 5977E mass spectrometer (Santa Clara, USA). 1 μL of sample was injected in split mode at 240 o C with a ratio of 1:50. Helium was used as the carrier gas and set at 1 mL/min. Samples were separated on a capillary CG column (ZB-Frame, Zebron,60 m×250 um i.d., 0.20 μm film thickness). The oven temperature was set at 50°C for 1,5 min, ramped to 190°C at 30°C/min and held for 5 min, then ramped to 230°C at 8°C/min, held for 5 min (The total analysis time was approximately 21 min). The front inlet has been set to 240°C while AUX temperature has been set to 280°C. Linearity was obtained between 3 -750 μmol/L, recovery rate was 89-112% and analytical CV was < 5% for all PUFAs. Sepsis is defined as a dysregulated and deleterious host response to infection leading to organ dysfunction. For COVID-19, in addition to lung injury, impaired liver and kidney function, and microcirculatory dysfunction, patients who met the criteria based on the Sepsis-3 International Consensus were defined as sepsis. According to this, organ dysfunction can be identified as an acute change in total Sequential Organ Failure Assessment (SOFA) score ≥2 points consequent to the infection [21, 22] . Renal functions of the patients included in the study were also evaluated. Acute Kidney Injury (AKI) is defined as an abrupt (within hours) decrease in kidney function, which encompasses both injury (structural damage) and impairment (loss of function). Overall, AKI was defined according to the KDIGO criteria [22] . All statistical analyzes were done with SPSS 22.0. Tests of normality were carried out with visual (histograms, possibility graphs) and analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk tests). The results are expressed as mean ± SD for parametric variables while, median (25-75 percentile) for non-parametric variables. The comparisons between groups of parametrical variables were analyzed with Independent-Samples t test, and nonparametric ones were analyzed by Mann-Whitney U test. Correlation analyses for parametric variables were done with Pearson test, while non-parametric ones were done with Spearman test. p<0.05 was accepted as the limit of statistical significance. A total of 106 patients divided into 3 subgroups according to IL-6 levels as described above were included in the study. Distribution and comparison results of demographics data like age and gender, and laboratory parameters including IL-6, CRP, D-dimer, PCT, Neutrophil, Lymphocyte, NLR with the rate of mortality were presented in Table- 1. Here, mortality rate was the lowest in group 1, while it increased in group 2 and highest mortality rate was seen in group 3 (p< 0.001 for all). When the laboratory parameters were evaluated; a statistically significant difference was seen among all three groups in terms of IL-6, CRP, PCT and D-dimer. There was not a statistically significant difference between neutrophil count and NLR in group 1 and group 2, while a statistically difference was observed between group 1 and group 3 and group 2 and group 3. ( Table 1) . Two patients from group 1, 25 patients from group 2 and 27 patients from group 3 were treated in ICU. Although not presented in the table, the mean hospitalization durations were 13.6, 17.6 and 19.6 days for groups 1,2 and 3 respectively. Length of stay in ICU were 13.5, 12.64, 13.81 days respectively. No statistically significant difference was found between hospital stay duration among groups. Ratio of patients treated in the ICU were 6.25%, 55.6% and 93.1% for the 3 groups, respectively while the mortality rates in the ICU were 50%, 80% and 96.3%, respectively. When ICU patients are evaluated in detail according to patient groups; pneumonia was detected in one of the 2 patients in group 1 and sepsis was detected in the other. Complications observed in ICU patients in group 2; 23 had pneumonia, 11 had sepsis, 6 had Acute Kidney Injury (AKI). And finally, in group 3; all patients had pneumonia, 13 had sepsis, 14 had AKI. In addition, a total of 8 patients required invasive mechanical ventilation (2 from group 1 and 6 from group 2). We evaluated 7 different EM PUFAs in the present study. Six different index data obtained by summing and dividing the values of these PUFAs with the current PUFAs values and the statistical results obtained from their comparison are presented in Table 2 . It is noteworthy here that the GLA values and the ω-6/ω-3 index were significantly different among all 3 Groups when compared individually and together. 4 of these 7 PUFAs, OA, EPA, ALA and DHA as well as ω-3 index, total ω-3, total ω-6, LA/ALA ratio and AA/EPA ratio have also been shown to have statistically significant differences in overall comparison of all patient groups (Table 2, Figure 1 ). In the correlation analysis between inflammatory markers and ω-3 PUFA levels; a weak/moderate negative correlation was found between ALA and IL-6, PCT, D-dimer and CRP. The most significant correlation was observed between ALA and IL-6 (r=-0.407, p< 0.001). Among other PUFAs, EPA and DHA have also shown weakly negative correlations with IL-6 levels ( Figure 2a) . When the correlation between ω-6 PUFAs and inflammatory markers were analyzed; weakly positive correlations were observed between LA and D-dimer, PCT and IL-6 while again a weakly positive correlation was observed between GLA and PCT and D-dimer (Figure 2b ). For the correlation between ω PUFA indices and inflammatory markers; we can conclude that total ω-6 index showed moderately positive correlation with IL-6, PCT and D-dimer levels. On the other hand, ω-3 index showed a moderately negative correlation with IL-6. There were also moderately negative correlations between total ω-3 and IL-6 and PCT (Figure 2c) . It has been revealed that IL-6 production is triggered by viral load, especially in severe COVID-19 cases [23] . During this infection, CD4+ T lymphocytes transform into pathogenic Th1 cells which is known to stimulate the release of GM-CSF and proinflammatory cytokines and activate monocytes with high IL-6 levels [24] . We designed our study by dividing COVID-19 patients into 3 different groups with 2 different cut-off values that we pre-determined for IL-6 levels. As is known, the presence and ratios of ω6 (AA, DGLA, GLA) and ω3 (EPA and DHA) PUFAs in the cell membrane depend on their conversion from nutrients and their precursors LA and ALA which are essential [7] . Conversion of LA to AA is much more effective than conversion of ALA to EPA/DHA. In addition to their competition for COX and LOX enzymes, ω-6 and ω-3 fatty acids also compete for elongation and desaturation enzymes and phospholipids. Therefore, in addition to the presence or absence of dietary intake of these FAs, inflammation may also affect their concentrations among cell membrane phospholipids. Consequently, the balance between the pro-/anti-inflammatory process can be modulated [25] . In the light of this information and considering the superiority of membrane FAs over plasma due to not being affected by short-term dietary intakes, we evaluated EM FAs of COVID-19 patients [26] . As the result, significant differences were observed between the patient groups in 4 of 7 PUFAs. A significant decrease was observed in an increasing manner from Group1 to 3 in terms of ω-3 PUFAs; ALA, EPA and DHA while GLA levels and ω-6/ω-3 ratio was significantly increased in all in all patient groups compared. All these changes are in line with the change in the severity of COVID-19, as expected. In addition, the LA/ALA ratio was found to be significantly lower in Group1 compared to other two groups, and the AA/EPA ratio was significantly lower only in Group1 compared to Group 3. The prominent finding of the study, which should be especially emphasized here, is the AA/EPA ratio. When the PUFAs, indices and ratios with the IL-6, CRP, D-dimer and PCT levels taken into consideration together, it was determined that the AA/EPA ratio showed a significantly positive correlation only with IL-6 ( Figure 2d ). Besides, AA/EPA ratio was only significant in the comparison of Group1 and Group 3 patients (Table-2 ). This also means that this parameter comes to the forefront in the patient group with a mortality rate around 90%, and it is related to IL-6 levels, independent of other parameters (Figure 2d ). Another point worth considering while calculating this ratio is AA levels did not show a significant difference between groups. As is known, AA plays a crucial role in inflammation and cytokine production [27] . Spangelo et al. showed that the AA-induced increase in IL-6 release from macrophages was attenuated in the presence of a COX inhibitor [28] . On the other hand, there are also studies showing that alveolar macrophages release AA and other bioactive lipids (lipoxin A4 etc.) to inactivate pathogens and suppress microbial infections [29] [30] [31] [32] . This means there are conflicting results regarding AA levels in different clinical studies evaluating inflammatory processes. This reveals that the pro/anti-inflammatory balance is not based on a single parameter, but it is also affected by the intermediate PUFAs synthesized from LA and ALA and even their ratios during the process. Considering the knowledge that AA and EPA are both synthesized by the same enzyme steps (Δ5 desaturase, elongase ve Δ6 desaturase reactions, respectively) from LA and ALA, the importance of the AA/EPA ratio seems more important in the balance between pro and antiinflammatory pathways compared to evaluation of AA and EPA individually. These results suggest that the AA/EPA ratio can be a marker of systemic inflammation like IL-6, and also an indicator of mortality, and it has a possible negative association with lung function [33] . The levels of LA (an ω-3 FA) among PUFAs did not differ between groups while ALA (an ω-6 FA) levels were found to be low especially in patients considered as high-risk group for mechanical ventilation and intubation during their hospital stay (group 2 and 3). In comparison of LA/ALA ratios, it was observed that there was an increasing trend from Group 1 to Group 3 (Table 2) . Moreover, while a significant negative correlation was observed between ALA and evaluated inflammatory parameters (IL-6, CRP, D-dimer and PCT), no correlation was observed between LA and any of these parameters. Also, again in correlation analysis the correlation values (p values) of LA/ALA ratio with the other four parameters have lower p values compared to ALA individually. We think this finding is substantial because this shows us that starting from essential FAs LA and ALA, which are considered precursors for PUFAs, the ratios of FAs in the same step may be more valuable [8] . In the literature, there are studies showing that EPA and DHA can inhibit IL-6 production by venous endothelial cells [34] . Moreover, supplementation of ˃2 g EPA-DHA/day to the diet of healthy individuals has been shown to reduce IL-6 production by mononuclear cells [35, 36] . The EPA, DHA, ω-3 index values which show a significant decrease from Group1 to Group3 in our study, and the total ω-3 values obtained by adding ALA to these, are compatible with these current literature findings. Although, our study does not aim to directly evaluate the effect of nutritional status or nutritional supplements on the development of pneumonia in COVID-19 patients, it highlights the importance of revealing long-term data on ω6/ω3 ratios by evaluating the EM fatty acid levels and the subgroups of these PUFAs. As a matter of fact, ω6/ω3 imbalance allows us to have an idea about the need for necessary reinforcement, especially in the high-risk group patients. By the simplest definition, ω-3 PUFAs inhibit the conversion of LA to ALA, the precursor of PGE2, and decreased production of PGE2 consequently leads to the diminished production of inflammatory cytokines [37] . This is supported by our study with both the ω3 index and the significant negative correlation between total ω3 and IL-6, and the significant positive correlations between total ω6 and IL-6, and also between ω6/ω3 and all other parameters, including IL-6 ( Figure 2c and 2d) . It is also important that the change in ω6/ω3 and LA/ALA levels among groups and the relation of these data with the increase in the incidence of mortality ( Table 1) . One of the other important findings of our study is that only EM GLA levels of ω6 PUFAs differed significantly between groups. In addition, a positive correlation was observed between GLA, PCT and IL-6. LA levels also showed a positive correlation with D-dimer levels in addition to PCT and IL-6. Unfortunately, the literature evaluating plasma or EM PUFAs together with systemic inflammation markers in COVID-19 patients is limited. On the other hand, there are studies investigating the significance of these markers. In the study conducted by Liu et al. to evaluate the predictive values of IL-6, CRP and PCT for severity of COVID-19 cases; it was shown that elevations in levels of these inflammatory markers were significantly higher in vast majority of severe patients when compared to mild cases [38] . They also indicated that these findings are consistent with the concept of cytokine storm as the result of cox proportional hazard model analysis which proofs the usage of these factors as independent factors to predict the severity of COVID-19. However, these findings still need to be studied further using a larger sample size. Our study is the first report in the literature showing a significant positive correlation of ω6 PUFAs and especially GLA and LA levels with PCT and negative correlation of ALA and ω3 PUFAs. The difference between PCT levels among groups and correlations with GLA and total ω3 FAs can point to the fact that PCT can be assumed as an indicator of systemic response caused by infection rather than other causes and/or to support proinflammatory process activity. The rate-limiting enzyme Δ6 desaturase, which catalyzes the metabolic pathway from LA to GLA, is very slow. After synthesis, GLA is rapidly extended to DGLA by elongase, and DGLA is acetylated and incorporated into cell membrane phospholipids. A small amount is also converted to AA [39] . The reason why only GLA levels were found to be significantly different between groups may be explained that the level of Δ6 desaturase enzyme is affected at different levels in different patients. Although there are no current studies that directly evaluate the level of Δ6 desaturase in diseases like COVID-19 or other inflammatory diseases causing pneumonia, in a number of cancer studies; knock-downed or inhibited Δ6 desaturase enzyme was shown to reduce expression of IL-6 and TNF-α and thereby causing a decrease in overall inflammation [40] . Of course, it should be kept in mind that this enzyme is also the enzyme that catalyzes the first step in the synthesis of EPA and DHA from ALA. This situation reveals that the related enzyme activation may differ between the patient groups in our study, depending on IL-6 levels. This also suggests that our findings are new and valuable in this sense. The present study does pose some limitations as follows: The patient number was relatively limited, the level of prostaglandins and leukotrienes were not detected and other possible mediators that could take part in the formation of cytokine storm like lipoxin A4, resolvin etc. were not evaluated. But as this is the first study in the literature to evaluate EM PUFAs in COVID-19 patients, it can form a basis for future more detailed studies evaluating the membrane FA composition and their metabolism related to cytokine storm in a larger perspective. In conclusion, detailed analysis of PUFAs can provide valuable information in the management of dietary intake or supplementation of PUFAs, which are believed to be deficient and are considered responsible for the severity of COVID-19. In addition to individual measurements of PUFAs, evaluation of the ratios like ω-6/ω-3, LA/ALA and AA/EPA rose to prominence in the management of inflammation-related diseases. ω-3 PUFAs, and AA/EPA ratio, like IL-6, is a marker of systemic inflammation, an indicator of mortality, suggesting that it may have a possible negative association with lung function in COVID-19 patients. All authors have consent to publication. Data is available from the Gulhane Training and Research Hospital, Department of Clinical Biochemistry upon request. Authors have no conflict of interest. Total ω-6: LA+GLA+DGLA+AA Coronavirus pathogenesis A new coronavirus associated with human respiratory disease in China Clinical features of patients infected with 2019 novel coronavirus in Wuhan Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol How COVID-19 induces cytokine storm with high mortality Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 Dietary polyunsaturated fatty acids and inflammatory mediator production Fatty acids as modulators of the immune response Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19 Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 Interleukine-6 in critically ill COVID-19 patients: A retrospective analysis Retrospective analysis of laboratory testing in 54 patients with severe-or critical-type 2019 novel coronavirus pneumonia IL-6 may be a good biomarker for earlier detection of COVID-19 progression The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) SARS-CoV-2 and viral sepsis: observations and hypotheses Acute Kidney Injury: Definition, Pathophysiology and Clinical Phenotypes Interleukin-6: A Masterplayer in the Cytokine Network MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases Comparison of plasma and erythrocyte membrane fatty acid compositions in patients with end-stage renal disease and type 2 diabetes mellitus Prostaglandin E(2)-induced interleukin-6 release by a human airway epithelial cell line Induction of interleukin-6 release by interleukin-1 in rat anterior pituitary cells in vitro: evidence for an eicosanoiddependent mechanism Bioactive Lipids in COVID-19-Further Evidence In vitro mimicry of essential fatty acid deficiency in human endothelial cells by TNFα impact of ω-3 versus ω-6 fatty acids Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6 N-3 PUFA supplementation, monocyte PCA expression and interleukin-6 production Inhibition of tumour necrosis factor-and interleukin-6 production by mononuclear cells following dietary fish-oil supplementation in healthy men and response to antioxidant co-supplementation N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19 Nutrition and Lifestyle in Neurological Autoimmune Diseases Inhibiting delta-6 desaturase activity suppresses tumor growth in mice